145 related articles for article (PubMed ID: 18180999)
1. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations.
Miao N; Pingpank JF; Alexander HR; Steinberg SM; Beresneva T; Quezado ZM
Ann Surg Oncol; 2008 Mar; 15(3):815-23. PubMed ID: 18180999
[TBL] [Abstract][Full Text] [Related]
2. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series.
Fitzpatrick M; Richard Alexander H; Deshpande SP; Martz DG; McCormick B; Grigore AM
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):647-51. PubMed ID: 24290749
[TBL] [Abstract][Full Text] [Related]
3. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
[TBL] [Abstract][Full Text] [Related]
4. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
5. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
7. Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma.
Chandrasekhar S; Perez M; Niaz Z; Ekram J; Lal N; Koly S; Cao B; Zager JS; Alomar M
Cancer Control; 2024; 31():10732748241246898. PubMed ID: 38605434
[TBL] [Abstract][Full Text] [Related]
8. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Isolated Hepatic Perfusion: Hemodynamic Monitoring and Goal-Directed Anesthetic Management: A Case Report.
Martin-Delgado O; Rodriguez M; Lopez A; Reina MA; De Vicente E; Quijano Y; Echenagusia A; Martinez JA
A A Case Rep; 2017 Jun; 8(11):300-303. PubMed ID: 28328586
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
Pingpank JF; Libutti SK; Chang R; Wood BJ; Neeman Z; Kam AW; Figg WD; Zhai S; Beresneva T; Seidel GD; Alexander HR
J Clin Oncol; 2005 May; 23(15):3465-74. PubMed ID: 15908655
[TBL] [Abstract][Full Text] [Related]
13. Isolated hepatic perfusion for metastatic melanoma.
Yamamoto M; Zager JS
J Surg Oncol; 2014 Mar; 109(4):383-8. PubMed ID: 24166748
[TBL] [Abstract][Full Text] [Related]
14. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
[TBL] [Abstract][Full Text] [Related]
16. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
[TBL] [Abstract][Full Text] [Related]
17. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
[TBL] [Abstract][Full Text] [Related]
18. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.
Rashid OM; Sloot S; Zager JS
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1355-64. PubMed ID: 25176398
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion.
Uzgare RP; Sheets TP; Johnston DS
Anticancer Res; 2013 May; 33(5):1989-2000. PubMed ID: 23645748
[TBL] [Abstract][Full Text] [Related]
20. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
